Abstract
The production of reactive species causes oxidative modifications of proteins accompanied by a loss of protein function. By protein oxidation all cellular compartments and any amino acid are effected. This might result in a defect of cellular homeostasis. Therefore, the degradation of non-functional, oxidized proteins is an essential function of the proteolytic branch of the antioxidant defense machinery. The major proteolytic system responsible for the removal of oxidized proteins is the proteasomal system. Whereas moderately oxidized proteins are more sensitive to proteolytic attack, severely oxidized ones are often poor substrates and might, however, inhibit the proteasome. This paper reviews the data available on protein modifications following oxidative stress, the cellular responses and the role of proteasome in this process.
Keywords: Reactive species, oxidative stress, protein oxidation, proteolysis, proteasome
Current Pharmaceutical Design
Title: Protein Pool Maintenance During Oxidative Stress
Volume: 15 Issue: 26
Author(s): B. Catalgol and T. Grune
Affiliation:
Keywords: Reactive species, oxidative stress, protein oxidation, proteolysis, proteasome
Abstract: The production of reactive species causes oxidative modifications of proteins accompanied by a loss of protein function. By protein oxidation all cellular compartments and any amino acid are effected. This might result in a defect of cellular homeostasis. Therefore, the degradation of non-functional, oxidized proteins is an essential function of the proteolytic branch of the antioxidant defense machinery. The major proteolytic system responsible for the removal of oxidized proteins is the proteasomal system. Whereas moderately oxidized proteins are more sensitive to proteolytic attack, severely oxidized ones are often poor substrates and might, however, inhibit the proteasome. This paper reviews the data available on protein modifications following oxidative stress, the cellular responses and the role of proteasome in this process.
Export Options
About this article
Cite this article as:
Catalgol B. and Grune T., Protein Pool Maintenance During Oxidative Stress, Current Pharmaceutical Design 2009; 15 (26) . https://dx.doi.org/10.2174/138161209789058129
DOI https://dx.doi.org/10.2174/138161209789058129 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Psoriatic Arthritis and its Novel Therapeutics
Current Rheumatology Reviews Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets <i>In Silico</i> Study of the Active Compounds of <i>Lindera aggregata</i> (Sims) Kosterm as Anti-coronavirus
Current Nutrition & Food Science Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNAs and Cardiac Conduction
Current Drug Targets Morphine as a Potential Oxidative Stress-Causing Agent
Mini-Reviews in Organic Chemistry Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Halving Your Cake and Eating it, Too: A Case-based Discussion and Review of Metabolic Rehabilitation for Obese Adults with Diabetes
Current Diabetes Reviews